Solutions

Online Inquiry

Name *

Email *

Phone *

Services Interested *

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Developmental and Reproductive Toxicology Evaluation for Cancer Drugs

Developmental and reproductive toxicology (developmental & reproductive toxicology) evaluation is essential in assessing the impact of cancer drugs on reproductive health and developmental processes. At Alfa Cytology, we provide comprehensive developmental & reproductive toxicology evaluation services to ensure that cancer drugs are safe for use in populations that include pregnant women and individuals of reproductive age. Our goal is to identify any potential risks to fertility, embryonic development, and postnatal development, supporting the creation of safe and effective cancer therapies.

Mechanisms of Developmental & Reproductive Toxicology

Cancer drugs, while essential for treating malignancies, can pose significant risks to reproductive health and developmental processes. These risks arise because many cancer drugs are designed to target rapidly dividing cells, a characteristic of both cancer cells and cells involved in reproduction and development.

Stages of reproduction of humans and rats (an example of a test animal) are shown Fig.1 Timeline of reproductive and developmental toxicity testing. (Niethammer, M., et al., 2022)

Cancer drugs, vital for treating malignancies, can harm reproductive health and development due to their impact on rapidly dividing cells. These drugs induce DNA damage, disrupt cell division, interfere with hormones, and generate oxidative stress. In males, they can reduce sperm count and testosterone levels, while in females, they may deplete ovarian reserves and disrupt menstrual cycles. Exposure during pregnancy can cause birth defects, low birth weight, and developmental delays. At Alfa Cytology, our developmental and reproductive toxicology evaluations assess these risks, ensuring safer cancer treatments that preserve reproductive health.

Our Services

Cancer drugs, due to their powerful therapeutic effects, can pose risks to reproductive health and fetal development. These risks must be thoroughly evaluated to prevent adverse outcomes such as infertility, teratogenic effects, and developmental delays. Developmental and reproductive toxicology studies help identify these risks, guiding safe drug use and regulatory compliance.

Fertility and Early Embryonic Development Studies:
Objective: Assess the effects of cancer drugs on reproductive performance and early embryonic development in male and female animals.
Methods: Evaluate parameters such as mating behavior, fertility indices, early embryonic mortality, and implantation rates.

Embryo-Fetal Development Studies:
Objective: Investigate the effects of cancer drugs on fetal development during pregnancy.
Methods: Administer the drug to pregnant animals and evaluate fetal growth, morphological development, and teratogenic effects.

Pre- and Postnatal Development Studies:
Objective: Examine the impact of cancer drugs on offspring from birth through weaning and into adulthood.
Methods: Assess parameters such as birth weight, physical development, neurobehavioral performance, and reproductive capability of offspring.

Reproductive Toxicity Studies:
Objective: Determine the potential of cancer drugs to impair reproductive function and fertility in both sexes.
Methods: Conduct multi-generation studies to observe long-term effects on reproductive health and function.

At Alfa Cytology, our Developmental and Reproductive Toxicology Evaluation services are dedicated to ensuring the safety and efficacy of cancer drugs for all patient populations. Our team of expert toxicologists uses advanced methodologies to provide comprehensive assessments that meet regulatory standards and support informed decision-making. Partner with us to safeguard reproductive health and developmental safety in your drug development programs. Contact us today to learn more about our developmental & reproductive toxicology evaluation services and how we can support your research and development efforts.

Reference

Niethammer, M., et al.; (2022). In vitro models of human development and their potential application in developmental toxicity testing. Development, 149(20), dev200933.

For research use only.